Factors predicting early mortality after new diagnosis of myelodysplastic syndrome: A population-based study

Annie M. Jacobsen, Jenny N. Poynter, Michaela R. Richardson, Phuong L Nguyen, Betsy Hirsch, Adina Cioc, Michelle A. Roesler, Erica D. Warlick

Research output: Contribution to journalArticle

Abstract

Objective: Little prospective data regarding factors determining patient outcomes in myelodysplastic syndromes (MDS) are available. To establish features of early mortality in MDS, we compare characteristics of patients dying within 1 year of diagnosis with those surviving longer. Methods: We prospectively enrolled adults with a new MDS diagnosis in a population-based case-control study. Logistic regression was used to calculate odds ratios and 95% confidence intervals for potential predictors of early mortality. Subgroup analyses were conducted within the following groups: high-/very-high-risk IPSS-R; very-low-/low-/intermediate-risk IPSS-R; treated patients; and supportive care only patients. Results: We observed early mortality in those with abnormal cytogenetics (OR: 3.36, 95% CI: 1.52-7.46), three or greater cytogenetic abnormalities (OR: 3.48, 95% CI: 1.51-7.99), treatment at a community medical center (versus academic) (OR: 2.55, 95% CI: 1.18-5.47), and with 2-3 concurrent medical comorbidities (OR: 2.14, 95% CI: 1.08-4.22). Similarly, in subgroup analyses, abnormal cytogenetics remained the main predictor of early mortality. Conclusion: Complex cytogenetics and prognostic risk category have been associated with early mortality without intervention. Our data confirm these associations in a large, prospectively followed cohort and highlight the significance of cytogenetic abnormalities and complexity regardless of IPSS-R risk categorization or treatment.

Original languageEnglish (US)
Pages (from-to)56-63
Number of pages8
JournalEuropean Journal of Haematology
Volume103
Issue number1
DOIs
StatePublished - Jul 1 2019
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Mortality
Population
Cytogenetics
Chromosome Aberrations
Cytogenetic Analysis
Case-Control Studies
Comorbidity
Patient Care
Logistic Models
Odds Ratio
Confidence Intervals
Therapeutics

Keywords

  • myelodysplastic syndrome
  • prospective
  • survival

ASJC Scopus subject areas

  • Hematology

Cite this

Jacobsen, A. M., Poynter, J. N., Richardson, M. R., Nguyen, P. L., Hirsch, B., Cioc, A., ... Warlick, E. D. (2019). Factors predicting early mortality after new diagnosis of myelodysplastic syndrome: A population-based study. European Journal of Haematology, 103(1), 56-63. https://doi.org/10.1111/ejh.13243

Factors predicting early mortality after new diagnosis of myelodysplastic syndrome : A population-based study. / Jacobsen, Annie M.; Poynter, Jenny N.; Richardson, Michaela R.; Nguyen, Phuong L; Hirsch, Betsy; Cioc, Adina; Roesler, Michelle A.; Warlick, Erica D.

In: European Journal of Haematology, Vol. 103, No. 1, 01.07.2019, p. 56-63.

Research output: Contribution to journalArticle

Jacobsen, AM, Poynter, JN, Richardson, MR, Nguyen, PL, Hirsch, B, Cioc, A, Roesler, MA & Warlick, ED 2019, 'Factors predicting early mortality after new diagnosis of myelodysplastic syndrome: A population-based study', European Journal of Haematology, vol. 103, no. 1, pp. 56-63. https://doi.org/10.1111/ejh.13243
Jacobsen, Annie M. ; Poynter, Jenny N. ; Richardson, Michaela R. ; Nguyen, Phuong L ; Hirsch, Betsy ; Cioc, Adina ; Roesler, Michelle A. ; Warlick, Erica D. / Factors predicting early mortality after new diagnosis of myelodysplastic syndrome : A population-based study. In: European Journal of Haematology. 2019 ; Vol. 103, No. 1. pp. 56-63.
@article{23de4d63c48c44b39345c811ae7f3eec,
title = "Factors predicting early mortality after new diagnosis of myelodysplastic syndrome: A population-based study",
abstract = "Objective: Little prospective data regarding factors determining patient outcomes in myelodysplastic syndromes (MDS) are available. To establish features of early mortality in MDS, we compare characteristics of patients dying within 1 year of diagnosis with those surviving longer. Methods: We prospectively enrolled adults with a new MDS diagnosis in a population-based case-control study. Logistic regression was used to calculate odds ratios and 95{\%} confidence intervals for potential predictors of early mortality. Subgroup analyses were conducted within the following groups: high-/very-high-risk IPSS-R; very-low-/low-/intermediate-risk IPSS-R; treated patients; and supportive care only patients. Results: We observed early mortality in those with abnormal cytogenetics (OR: 3.36, 95{\%} CI: 1.52-7.46), three or greater cytogenetic abnormalities (OR: 3.48, 95{\%} CI: 1.51-7.99), treatment at a community medical center (versus academic) (OR: 2.55, 95{\%} CI: 1.18-5.47), and with 2-3 concurrent medical comorbidities (OR: 2.14, 95{\%} CI: 1.08-4.22). Similarly, in subgroup analyses, abnormal cytogenetics remained the main predictor of early mortality. Conclusion: Complex cytogenetics and prognostic risk category have been associated with early mortality without intervention. Our data confirm these associations in a large, prospectively followed cohort and highlight the significance of cytogenetic abnormalities and complexity regardless of IPSS-R risk categorization or treatment.",
keywords = "myelodysplastic syndrome, prospective, survival",
author = "Jacobsen, {Annie M.} and Poynter, {Jenny N.} and Richardson, {Michaela R.} and Nguyen, {Phuong L} and Betsy Hirsch and Adina Cioc and Roesler, {Michelle A.} and Warlick, {Erica D.}",
year = "2019",
month = "7",
day = "1",
doi = "10.1111/ejh.13243",
language = "English (US)",
volume = "103",
pages = "56--63",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Factors predicting early mortality after new diagnosis of myelodysplastic syndrome

T2 - A population-based study

AU - Jacobsen, Annie M.

AU - Poynter, Jenny N.

AU - Richardson, Michaela R.

AU - Nguyen, Phuong L

AU - Hirsch, Betsy

AU - Cioc, Adina

AU - Roesler, Michelle A.

AU - Warlick, Erica D.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Objective: Little prospective data regarding factors determining patient outcomes in myelodysplastic syndromes (MDS) are available. To establish features of early mortality in MDS, we compare characteristics of patients dying within 1 year of diagnosis with those surviving longer. Methods: We prospectively enrolled adults with a new MDS diagnosis in a population-based case-control study. Logistic regression was used to calculate odds ratios and 95% confidence intervals for potential predictors of early mortality. Subgroup analyses were conducted within the following groups: high-/very-high-risk IPSS-R; very-low-/low-/intermediate-risk IPSS-R; treated patients; and supportive care only patients. Results: We observed early mortality in those with abnormal cytogenetics (OR: 3.36, 95% CI: 1.52-7.46), three or greater cytogenetic abnormalities (OR: 3.48, 95% CI: 1.51-7.99), treatment at a community medical center (versus academic) (OR: 2.55, 95% CI: 1.18-5.47), and with 2-3 concurrent medical comorbidities (OR: 2.14, 95% CI: 1.08-4.22). Similarly, in subgroup analyses, abnormal cytogenetics remained the main predictor of early mortality. Conclusion: Complex cytogenetics and prognostic risk category have been associated with early mortality without intervention. Our data confirm these associations in a large, prospectively followed cohort and highlight the significance of cytogenetic abnormalities and complexity regardless of IPSS-R risk categorization or treatment.

AB - Objective: Little prospective data regarding factors determining patient outcomes in myelodysplastic syndromes (MDS) are available. To establish features of early mortality in MDS, we compare characteristics of patients dying within 1 year of diagnosis with those surviving longer. Methods: We prospectively enrolled adults with a new MDS diagnosis in a population-based case-control study. Logistic regression was used to calculate odds ratios and 95% confidence intervals for potential predictors of early mortality. Subgroup analyses were conducted within the following groups: high-/very-high-risk IPSS-R; very-low-/low-/intermediate-risk IPSS-R; treated patients; and supportive care only patients. Results: We observed early mortality in those with abnormal cytogenetics (OR: 3.36, 95% CI: 1.52-7.46), three or greater cytogenetic abnormalities (OR: 3.48, 95% CI: 1.51-7.99), treatment at a community medical center (versus academic) (OR: 2.55, 95% CI: 1.18-5.47), and with 2-3 concurrent medical comorbidities (OR: 2.14, 95% CI: 1.08-4.22). Similarly, in subgroup analyses, abnormal cytogenetics remained the main predictor of early mortality. Conclusion: Complex cytogenetics and prognostic risk category have been associated with early mortality without intervention. Our data confirm these associations in a large, prospectively followed cohort and highlight the significance of cytogenetic abnormalities and complexity regardless of IPSS-R risk categorization or treatment.

KW - myelodysplastic syndrome

KW - prospective

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85066050675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066050675&partnerID=8YFLogxK

U2 - 10.1111/ejh.13243

DO - 10.1111/ejh.13243

M3 - Article

C2 - 31058390

AN - SCOPUS:85066050675

VL - 103

SP - 56

EP - 63

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 1

ER -